Head-to-head · WeighScore
Fifty 410 vs Nucific
The verdict
Fifty 410 takes it — 71.3/100 to 56.2/100.
Fifty 410 grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Fifty 410 is a direct-to-consumer weight-loss telehealth service offering personalized compounded semaglutide and tirzepatide prescribed by licensed providers and prepared by FDA-registered 503A and 503B…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Fifty 410 | Nucific |
|---|---|---|
| WeighScore | 71.3/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #94 | #417 |
| Semaglutide | $99/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $133/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #94 · C
Strengths
- Transparent public pricing from 99 dollars per month for semaglutide
- No membership or subscription; pay only for what you need
- Compounded by FDA-registered 503A and 503B pharmacies
- Fast 24 to 48 hour provider review
- Free one to two day shipping
Where it loses points
- Does not bill insurance directly
- Compounded GLP-1 is not an FDA-approved finished drug
- Specific clinician credentials are not publicly disclosed
- Served-states list is not published on the site
- No branded GLP-1 options
Graded #417 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.